The closing of screening for the TROPOS trial indicates progress in Keros' clinical development pipeline, which is a positive signal for investors. The expectation to complete enrollment by September and present data in Q2 2025 suggests a clear timeline for potential advancements, likely boosting investor confidence and positively impacting the stock price in the short term.